Transcode Therapeutics (RNAZ) Net Income (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Net Income came in at -$17.6 million in Q1 2026, down 45.25% YoY from -$32.1 million in Q1 2025, and down 9.8% on a QoQ basis from -$16.0 million in Q4 2025.
Transcode Therapeutics (RNAZ) Net Income (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 7 years of Net Income data on file, last reported at -$17.6 million in Q1 2026.
- Quarterly Net Income fell 45.25% year-over-year to -$17.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$42.4 million (down 72.38% YoY) and the FY2025 annual result came in at -$34.4 million, down 105.52% from the prior year.
- Net Income fell to -$17.6 million in Q1 2026, from -$16.0 million in the prior quarter.
- In the past five years, Net Income ranged from a high of -$2.3 million in Q3 2024 to a low of -$17.6 million in Q1 2026.
- A 5-year average of -$6.5 million and a median of -$5.2 million in 2024 frame the typical range for Net Income.
- Annual changes were most pronounced in 2022 — Net Income tumbled 600.38% — and 2024, when it jumped 58.46%.
- Tracing RNAZ's Net Income over 5 years: stood at -$5.5 million in 2022, then advanced by 25.31% to -$4.1 million in 2023, then retreated by 23.7% to -$5.1 million in 2024, then plunged by 214.46% to -$16.0 million in 2025, then declined by 9.8% to -$17.6 million in 2026.
- The last three Net Income figures came in at -$17.6 million (Q1 2026), -$16.0 million (Q4 2025), and -$4.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - | -6.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.55 Mn |
| Dec 31, 2025 | -15.99 Mn |
| Sep 30, 2025 | -4.63 Mn |
| Jun 30, 2025 | -4.23 Mn |
| Mar 31, 2025 | -12.09 Mn |
| Dec 31, 2024 | -5.08 Mn |
| Sep 30, 2024 | -2.28 Mn |
| Jun 30, 2024 | -5.15 Mn |
| Mar 31, 2024 | -3.40 Mn |
| Dec 31, 2023 | -4.11 Mn |
| Sep 30, 2023 | -5.48 Mn |
| Jun 30, 2023 | -5.31 Mn |
| Mar 31, 2023 | -5.01 Mn |
| Dec 31, 2022 | -5.50 Mn |
| Sep 30, 2022 | -5.64 Mn |
| Jun 30, 2022 | -5.75 Mn |
| Mar 31, 2022 | -3.52 Mn |
| Dec 31, 2021 | -2.91 Mn |
| Sep 30, 2021 | -7.15 Mn |
| Jun 30, 2021 | 2.77 Mn |